BioSpace News Archive

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2019 and provided an operational update.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and year ended December 31, 2019 and recent corporate highlights.

Company reports positive adoption trends for Dialysate Triferic® (ferric pyrophosphate citrate), highlighted by 77% increase in clinics under contract

Adverum Biotechnologies, Inc. reported financial results for the fourth quarter ended December 31, 2019 and provided a corporate update.

In parallel, board and management evaluating all potential strategic alternatives to maximize shareholder value and implementing cost containment efforts

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter and full year ended December 31, 2019.

IRIDEX Corporation reported financial results for the fourth quarter ended December 28, 2019.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.

BioDelivery Sciences International, Inc. reported strong financial results for the fourth quarter and full-year ended December 31, 2019, as well as the following operational and performance highlights.

Geron Corporation, a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, reported financial results for the fourth quarter and year ended December 31, 2019 as well as 2020 milestones.